Drug Information

Drug General Information
Drug ID
D03WAU
Former ID
DCL000049
Drug Name
Anamorelin
Drug Type
Small molecular drug
Indication Carbohydrate metabolism disorder [ICD10:E73-E74] Phase 3 [523546]
Company
Sapphire Therape.
Structure
Download
2D MOL

3D MOL
Formula
C31H42N6O3
Canonical SMILES
CC(C)(C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)N3CCCC(C3)(CC4=CC<br />=CC=C4)C(=O)N(C)N(C)C)N
InChI
1S/C31H42N6O3/c1-30(2,32)28(39)34-26(18-23-20-33-25-15-10-9-14-24(23)25)27(38)37-17-11-16-31(21-37,29(40)36(5)35(3)4)19-22-12-7-6-8-13-22/h6-10,12-15,20,26,33H,11,16-19,21,32H2,1-5H3,(H,34,39)/t26-,31-/m1/s1
InChIKey
VQPFSIRUEPQQPP-MXBOTTGLSA-N
PubChem Compound ID
9828911
PubChem Substance ID
14788118, 14861465, 24130575, 44927038, 77293057, 134338755, 140173272, 163620808, 163686134, 175267765, 185990433, 223395076, 227197611, 241054693, 242549596, 243353165, 252477647
Target and Pathway
Target(s) Growth hormone secretagogue receptor type 1 Target Info Stimulator [537066]
KEGG Pathway cAMP signaling pathway
Neuroactive ligand-receptor interaction
NetPath Pathway Leptin Signaling Pathway
Reactome Peptide ligand-binding receptors
G alpha (q) signalling events
WikiPathways GPCRs, Class A Rhodopsin-like
Gastrin-CREB signalling pathway via PKC and MAPK
Peptide GPCRs
GPCR ligand binding
GPCR downstream signaling
References
Ref 523546ClinicalTrials.gov (NCT01395914) Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study (ROMANA 3). U.S. National Institutes of Health.
Ref 537066Pharmacodynamic hormonal effects of anamorelin, a novel oral ghrelin mimetic and growth hormone secretagogue in healthy volunteers. Growth Horm IGF Res. 2009 Jun;19(3):267-73. Epub 2009 Feb 3.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.